Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients.

导出 OA

翻译打印收藏纠错

第一作者： Justin,de Brabander

第一单位： Amsterdam UMC, location University of Amsterdam, Center for Experimental and Molecular Medicine (CEMM), Amsterdam, The Netherlands j.debrabander@amsterdamumc.nl.

作者： Justin,de Brabander ^[1] ; Erik,Duijvelaar ^[2] ; Job R,Schippers ^[2] ; Patrick J,Smeele ^[2] ; Hessel,Peters-Sengers ^[3] ; Jan Willem,Duitman ^[4] ; Jurjan,Aman ^[2] ; Harm Jan,Bogaard ^[2] ; Tom,van der Poll ^[3] ; Lieuwe D J,Bos ^[5] ; CounterCOVID Study Group

作者单位： Amsterdam UMC, location University of Amsterdam, Center for Experimental and Molecular Medicine (CEMM), Amsterdam, The Netherlands j.debrabander@amsterdamumc.nl. ^[1] Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands. ^[2] Amsterdam UMC, location University of Amsterdam, Center for Experimental and Molecular Medicine (CEMM), Amsterdam, The Netherlands. ^[3] Amsterdam UMC, location University of Amsterdam, Department of Pulmonary Medicine, Amsterdam, The Netherlands.;Amsterdam UMC, location University of Amsterdam, Department of Experimental Immunology (EXIM), Amsterdam, The Netherlands. ^[4] Amsterdam UMC, location University of Amsterdam, Department of Pulmonary Medicine, Amsterdam, The Netherlands.;Amsterdam UMC, location University of Amsterdam, Department of Intensive Care and Laboratory of Experimental Intensive Care and Anesthesiology (LEICA), Amsterdam, The Netherlands. ^[5]

主题词人类(Humans);免疫调节(Immunomodulation);肺表面活性物质相关蛋白质D(Pulmonary Surfactant-Associated Protein D)

DOI 10.1183/13993003.00780-2022

PMID 35896211

发布时间 2024-09-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交